SCHEMBL939737

SCHEMBL939737

COC(=O)[C@H](C)NC(=O)OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
CTSK P43235 4/20 0.60
CTSL P07711 2/20 0.60
CTSS P25774 2/20 0.60
CTSB P07858 1/20 0.60
CAPN1 P07384 1/20 0.60
ATM Q13315 1/20 0.59
ALDH1A1 P00352 2/20 0.58
TRPM8 Q7Z2W7 1/20 0.58
ALOX15 P16050 1/20 0.58
MEN1 O00255 2/20 0.57
LMNA P02545 2/20 0.57
KMT2A Q03164 2/20 0.57
KYNU Q16719 1/20 0.56
CTRB1 P17538 2/20 0.56
ELANE P08246 1/20 0.56
CYP1A2 P05177 2/20 0.54
CYP3A4 P08684 2/20 0.54
CYP2C9 P11712 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5412160 1.00 MAPT (0.61) MAPTL3MBTL1CTSKCTSLCTSS
SCHEMBL7674223 1.00 MAPT (0.61) MAPTL3MBTL1CTSKCTSLCTSS
Hydrochloric Acid SCHEMBL6639219 0.98 MAPT (0.60) MAPTL3MBTL1CTSKCTSLCTSS
SCHEMBL27899929 0.94 CTSK (0.60) MAPTL3MBTL1CTSKCTSLCTSS
SCHEMBL19036901 0.94 CTSK (0.60) MAPTL3MBTL1CTSKCTSLCTSS
SCHEMBL12022502 0.94 CTSK (0.60) MAPTL3MBTL1CTSKCTSLCTSS
SCHEMBL15080869 0.92 CTSK (0.61) CTSKCTSLCTSSCTSBATM
SCHEMBL30946598 0.92 CTSK (0.61) CTSKCTSLCTSSCTSBATM
SCHEMBL5075275 0.90 CTSK (0.60) CTSKCTSLCTSSCTSBATM
SCHEMBL2627373 0.89 CTSK (0.59) CTSKCTSLCTSSCTSBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025245227-A1 BACTERIAL CELL WALL COMPONENTS AS PROBES FOR A LABEL-FREE BINDING ASSAY AND THE USE THEREOF ACADEMIA SINICA (TW) 2025-11-27 WO disclosed
WO-2025047793-A1 NOVEL COMPOUND HAVING ACTIVITY-ENHANCING EFFECT ON ANTIFUNGAL DRUGS, AND METHOD FOR PRODUCING SAME 学校法人北里研究所 2025-03-06 WO disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 EP disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 US disclosed
CN-116829949-A Compositions for detecting or measuring analytes 伯蒂斯有限公司 2023-09-29 CN disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 WO disclosed
EP-3687988-B1 ANTIBACTERIAL COMPOUND AND USES OF SAME BIOMERIEUX SA (FR) 2023-05-03 EP disclosed
EP-3687988-B1 ANTIBACTERIAL COMPOUND AND USES OF SAME BIOMERIEUX SA (FR) 2023-05-03 EP disclosed
US-20230121469-A1 CATALYST FOR MANUFACTURING AMIDE COMPOUND, AND METHOD FOR MANUFACTURING AMIDE COMPOUND CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) 2023-04-20 US disclosed
EP-4159739-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2023-04-05 EP disclosed
WO-2002026750-A2 PHOSPHINO-AMINOPHOSPHINES, CATALYST COMPLEXES AND ENANTIOSELECTIVE HYDROGENATION EASTMAN CHEMICAL COMPANY (US) 2002-04-04 WO disclosed
WO-2001046152-A1 HERBICIDAL DIACYL DERIVATIVES OF PROPYLENE DIAMINE MONSANTO TECHNOLOGY LLC (US) 2001-06-28 WO disclosed
US-6211235-B1 ALZHEIMERS DISEASE ELAN PHARMACEUTICALS, INC. 2001-04-03 US disclosed
US-6207710-B1 FOR THERAPY OF ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. 2001-03-27 US disclosed
US-6191166-B1 ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. 2001-02-20 US disclosed
EP-0942924-A2 METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS Elan Pharmaceuticals, Inc. (US) 1999-09-22 EP disclosed
WO-1998022494-A9 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS 1998-08-20 WO disclosed
WO-1998022494-A2 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS ELAN PHARMACEUTICALS, INC. (US) 1998-05-28 WO disclosed
EP-0321722-B1 Process for obtaining dipeptides DEGUSSA (DE) 1994-02-16 EP disclosed
EP-0321722-A2 Process for obtaining dipeptides Degussa Aktiengesellschaft (DE) 1989-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230121469-A1 CATALYST FOR MANUFACTURING AMIDE COMPOUND, AND METHOD FOR MANUFACTURING AMIDE COMPOUND NAAA, ASNS, BCAT2 MAPT 3585/4885L3MBTL1 3689/4885CTSK 778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.